GlucoTrack, Inc. is a healthcare technology company focused on the development of innovative non-invasive glucose monitoring solutions for individuals with diabetes. The company leverages advanced sensing technologies to create devices that enable users to track their blood glucose levels without the need for traditional fingerstick methods. GlucoTrack aims to improve the quality of life for diabetic patients by providing them with more convenient and accessible ways to manage their condition, while also enabling healthcare providers to better monitor patient health. Through its commitment to research and development, GlucoTrack seeks to contribute to more effective diabetes management and enhance overall patient outcomes. Read More
Glucotrack, Inc. (NASDAQ: GCTK) ("Glucotrack" or the "Company") today announced definitive agreements for approximately $5.5 million in financing from participating institutional investors, including a $2.0 million equity financing priced at $0.75 per unit and a $3.5 million follow-on investment in the form of convertible debt.
Gainers Nuwellis (NASDAQ:NUWE) stock moved upwards by 123.7% to $4.23 during Thursday's regular session. GlucoTrack (NASDAQ:GCTK) shares moved upwards by 79.85% to $0.51. The company's market cap stands at
Gainers Nuwellis (NASDAQ:NUWE) stock rose 119.0% to $4.14 during Thursday's pre-market session. GlucoTrack (NASDAQ:GCTK) stock increased by 47.36% to $0.42. The market value of their outstanding shares is at $1.8
Lōkahi Therapeutics™ Inc., a wholly owned subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), today announced progress in its LT-100 development strategy focused on evaluating whether a historical administration approach requiring up to 15 intradermal (ID) injections per treatment visit can be simplified to a single subcutaneous (SC) injection per visit. During a Type C meeting with the U.S. Food and Drug Administration in May 2026, the Company discussed its proposed clinical strategy for LT-100. Following that meeting, Lōkahi completed a nonclinical minipig study designed to compare systemic exposure following subcutaneous and intradermal administration of LT-100. The results provided important information to support the Company's planned clinical evaluation of a single-injection administration approach.
RUTHERFORD, N.J. and SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack" or the "Company"), together with its operating business Lōkahi Therapeutics™ ("Lōkahi"), a clinical-stage biopharmaceutical company advancing innovative non-opioid biologic therapies and applying its proprietary ai²™ methodology to identify and develop high-value healthcare opportunities, today announced the completion of a bridge financing designed to support the Company's strategic growth objectives, including the continued advancement of the combined Glucotrack–Lōkahi platform and other anticipated capital markets activities. The bridge financing follows the completion of the strategic business combination between Glucotrack and Lōkahi, announced on July 14, 2026.
Gainers GlucoTrack (NASDAQ:GCTK) stock moved upwards by 28.6% to $0.64 during Thursday's after-market session. The company's market cap stands at $3.3 million. Stereotaxis (AMEX:STXS) stock increased by 8.51%
Transaction positions the combined company to execute a capital-efficient, repeatable strategy leveraging public market access and Lōkahi Therapeutics ai²-driven asset sourcing, development, and advancement platform
Transaction positions the combined company to execute a capital-efficient, repeatable strategy leveraging public market access and Lōkahi Therapeutics ai²-driven asset sourcing, development, and advancement platform
RUTHERFORD, N.J., July 08, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (“Glucotrack”, or the “Company”) (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that the US Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application titled “Methods and Systems for Continuously Monitoring the Glucose Level of a Patient.” The allowed claims expand the intellectual property protecting the Company’s continuous blood glucose monitoring (CBGM) platform as it advances its multi-year, fully implantable CBGM system toward commercialization.
RUTHERFORD, N.J., May 26, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that company leadership will present on its fully implantable continuous blood glucose monitoring (CBGM) technology at the American Diabetes Association’s (ADA) 2026 Scientific Sessions, taking place in New Orleans, June 5 – 8, 2026.
